Skip to content

Treasury Stock at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$10M+32.2%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$53M+70.7%
Arrowhead Research logo
Arrowhead ResearchARWR
$53.19M
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$405.78M+25.5%
TG Therapeutics logo
TG TherapeuticsTGTX
$200.23M+1,225%

Other financials

Income statement

See full
Revenue$36.2M+77.5%
Gross profit$34.3M+80.1%
Operating income$52.1M+1,073%
Net income$37.9M+1,323%
EPS (diluted)$0.60+1,100%

Balance sheet

See full
Cash & equivalents$95.6M+156%
Total debt$1.1M-98.1%
Total equity$205.8M+402%
Total assets$278.6M+61.3%

Cash flow

See full
Operating cash flow$6.1M+175%
CapEx$35.0K-64.6%
Free cash flow$6.1M+173%

Valuation

See full
Market cap$773.23M+56.4%
Enterprise value$678.78M+30.8%
P/E6.2×
P/S6.3×-5.9×

Profitability

See full
Gross margin86.1%+7.2pp
Operating margin-103.9%-43.0pp
Net margin101.6%+60.1pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity100.7%+60.3pp
Debt / equity-1.5×
Current ratio4.9×+1.9×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockValue.

The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s treasury stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s treasury stock?
Zevra Therapeutics, Inc. (ZVRA) reported treasury stock of $10.98M in Q1 2026.
How has Zevra Therapeutics, Inc.'s treasury stock changed year-over-year?
Zevra Therapeutics, Inc.'s treasury stock decreased by 0.0% year-over-year, from $10.98M to $10.98M.
What does treasury stock mean?
Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.